.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Harvard Business School
Dow
Farmers Insurance
Mallinckrodt
Express Scripts
Novartis
Medtronic
Boehringer Ingelheim
US Army

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Carrier-antibody compositions and methods of making and using the same
Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
Inventor(s): Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:15/060,967
Patent Claims:1. A lyophilized nanoparticle composition comprising nanoparticles having an outer surface, wherein each of the nanoparticles comprises: a) albumin; b) between about 100 to about 1000 rituximab antibodies having an Fc portion and an antigen-binding portion; and c) paclitaxel; said nanoparticles being lyophilized, and wherein upon reconstitution with an aqueous solution antigen-binding portion of said antibodies are arranged on the outside surface of the nanoparticles and remain capable of binding to CD20 in vivo and wherein the average size of the nanoparticles is between 130 nm and 800 nm.

2. The lyophilized nanoparticle composition of claim 1 that is stable at about 20.degree. C. to about 25.degree. C. for at least 3 months.

3. The lyophilized nanoparticle composition of claim 1, wherein each of the nanoparticles comprises between about 400 and about 800 antibodies.

4. The lyophilized nanoparticle composition of claim 3, further wherein less than 0.01% of nanoparticles in the composition have a size greater than 800 nm.

5. The lyophilized nanoparticle composition of claim 1, wherein the average nanoparticle size in the composition is approximately 160 nm.

6. The lyophilized nanoparticle composition of claim 1, wherein the paclitaxel is located inside the nanoparticle, arranged on the outside surface of the nanoparticle, or both.

7. The nanoparticle composition of claim 1, wherein the antibodies arrange into a substantially single layer of antibodies on all or part of the surface of the nanoparticle.

8. The nanoparticle composition of claim 1, wherein the nanoparticles have a dissociation constant between about 1.times.10.sup.-11 M and about 1.times.10.sup.-3 M.

9. The lyophilized composition of claim 1, wherein the albumin is human serum albumin.

10. A lyophilized composition comprising nanoparticle complexes having an outer surface, wherein each of the nanoparticle complexes comprises: albumin; between about 100 to about 1000 rituximab antibodies, each having a Fc portion and a CD20-binding portion, wherein CD20-binding portions of the rituximab antibodies are arranged on the outer surface of the complex; and paclitaxel; said nanoparticle complexes being lyophilized, and wherein upon reconstitution with an aqueous solution the nanoparticle complexes remain capable of binding to CD20 in vivo and further wherein said complexes have an average size of from about 130 nm to about 800 nm; wherein the lyophilized composition does not contain a bulking agent.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
RITUXAN
rituximab
VIAL1037050011997-11-26► Subscribe Mayo Foundation for Medical Education and Research (Rochester, MN) Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Chinese Patent Office
Express Scripts
Federal Trade Commission
Healthtrust
Cipla
Dow
US Army
Fuji
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot